Sunday, October 4, 2009
This article addresses recent and upcoming developments regarding "reverse payment" pharmaceutical settlements, including: an unresolved circuit split, harmonization of Department of Justice ("DOJ") and Federal Trade Commission ("FTC") antitrust approaches, and a flurry of pending legislation. Proposals to ban reverse payments are gaining momentum and have...
